Subsequent Events - Additional Information (Details)	Oct. 22, 2020
Subsequent Event
Subsequent Event [Line Items]
Subsequent event, description	On October 22, 2020, the U.S. Food and Drug Administration cleared the Company’s Investigational New Drug (“IND”) application for ADI-001, an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor (“CAR”) targeting CD20 for treatment of non-Hodgkin’s lymphoma (“NHL”). The active IND enables the Company to initiate the first-in-human clinical trial to assess safety and efficacy of ADI-001 in NHL patients.

Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

Name:	us-gaap_SubsequentEventDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration